Last week, the Food and Drug Administration ignored the advice of its own expert advisory committee and approved the first new treatment for Alzheimer’s in 18 years. Called Aduhelm, it carries a substantial risk of painful brain swelling and bleeding, requires monthly infusions, and comes with an eye-popping list price of $56,000 per year. These caveats might be fine if[Read More...]
The post Why the Approval of That Alzheimer’s Drug Is So Disturbing appeared first on Countercurrents.
Source